BiotechTube

Comparator: A: Pregabalin + Comparator: B: Duloxetine + Comparator: C: Diphenhydramine hydrochloride

Phase 2Withdrawn
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Painful Diabetic Neuropathy

Conditions

Painful Diabetic Neuropathy

Trial Timeline

Apr 1, 2009 → Sep 1, 2009

NCT ID
NCT00837941

About Comparator: A: Pregabalin + Comparator: B: Duloxetine + Comparator: C: Diphenhydramine hydrochloride

Comparator: A: Pregabalin + Comparator: B: Duloxetine + Comparator: C: Diphenhydramine hydrochloride is a phase 2 stage product being developed by Merck for Painful Diabetic Neuropathy. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00837941. Target conditions include Painful Diabetic Neuropathy.

What happened to similar drugs?

7 of 20 similar drugs in Painful Diabetic Neuropathy were approved

Approved (7) Terminated (2) Active (11)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅Qutenza + PregabalinAstellas PharmaApproved
✅duloxetine hydrochlorideEli LillyApproved
✅duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved
✅pregabalinPfizerApproved
✅PregabalinPfizerApproved
✅PregabalinPfizerApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00837941Phase 2Withdrawn

Competing Products

20 competing products in Painful Diabetic Neuropathy

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placeboAstellas PharmaPhase 2
27
QUTENZAAstellas PharmaPhase 3
40
Qutenza + PregabalinAstellas PharmaApproved
43
duloxetine hydrochlorideEli LillyApproved
43
Duloxetine hydrochloride + placeboEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved
43
Duloxetine + Pregabalin + PlaceboEli LillyPhase 3
40
Placebo + Pregabalin + LY545694 21 mg + LY545694 49 mg + LY545694 105 mgEli LillyPhase 2
35
GRC 17356 + Matching PlaceboGlenmark PharmaceuticalsPhase 2
35
GRC 17536 (Medium Dose) + GRC 17536 (Low Dose) + PlaceboGlenmark PharmaceuticalsPhase 2
27
Tapentadol extended release (ER) + Oxycodone controlled release (CR)Johnson & JohnsonPhase 3
32
AZD5213 + pregabalin + Placebo + pregabalin capsulesAstraZenecaPhase 2
35
MEDI7352AstraZenecaPhase 2
27
MEDI7352AstraZenecaPhase 2
35
MEDI7352 + PlaceboAstraZenecaPhase 1
29
MK-6096 + PlaceboMerckPhase 2
35
EMA401 + PlaceboNovartisPhase 2
27
PregabalinPfizerPhase 3
40